MIND Institute, UC Davis Medical Center, Sacramento, 2825 50th Street, California, CA 95817, USA ; Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA.
Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
J Neurodev Disord. 2014;6(1):27. doi: 10.1186/1866-1955-6-27. Epub 2014 Jul 30.
The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5' untranslated region of the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation.
Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without neurological problems; those with ASD and neurological problems including seizures; and those with neurological problems without ASD.
We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6%) that were not found in approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The CNVs were more commonly identified in individuals with neurological involvement and ASD.
The frequencies were not statistically significant across the groups. There were no significant differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in premutation carriers with ASD and neurological involvement.
脆性 X 智力低下 1 基因(FMR1)5'非翻译区的 CGG 重复 55-200 个被定义为 FMR1 前突变。脆性 X 相关震颤/共济失调综合征(FXTAS)和脆性 X 相关原发性卵巢功能不全(FXPOI)已很好地描述了其临床受累情况。行为/精神和其他神经系统表现仍有待确定,以及将解释具有 FMR1 前突变个体中观察到的表型变异性的分子机制。
在这里,我们描述了一项对 56 名前突变范围为 55-192 重复的参与者的拷贝数变异(CNV)的小型试点研究。参与者根据四个不同的临床组进行分析:有行为问题但无自闭症谱系障碍(ASD)的参与者;有 ASD 但无神经系统问题的参与者;有 ASD 和包括癫痫在内的神经系统问题的参与者;以及有神经系统问题但无 ASD 的参与者。
我们在 11 例(19.6%)中发现了 12 种罕见的 CNV(8 种重复和 4 种缺失),在大约 8000 名对照中未发现。其中 3 种位于 10q26,2 种位于 Xp22.3,重叠面积较小。CNV 更常见于有神经系统受累和 ASD 的个体中。
组间无统计学意义。所有组之间的心理计量和行为评分均无显著差异。需要进一步研究来确定 FMR1 前突变个体中第二遗传打击的频率;然而,这些初步结果表明,基因组研究可有助于理解具有 ASD 和神经系统受累的前突变携带者临床受累的分子病因。